Pier 88 Investment Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pier 88 Investment Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,840	Closed	-$161K	–	98
2024 Q1	$161K	Buy	1,840 +70	+4%	+$6.27K	0.04%	91
2023 Q4	$171K	Sell	1,770 -2,600	-59%	-$230K	0.04%	84
2023 Q3	$387K	Buy	4,370 +3,440	+370%	+$306K	0.1%	81
2023 Q2	$80.6K	Sell	930 -70	-7%	-$6.59K	0.02%	89
2023 Q1	$97.2K	Buy	+1,000	New	+$104K	0.02%	85

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Pier 88 Investment Partners's BMRN Position: Q2 2024 in Review

Pier 88 Investment Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 1,840 shares — an estimated $161K sold.

Pier 88 Investment Partners first reported a position in BMRN in Q1 2023 and held it in 5 quarters. The position peaked at $387K in Q3 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Pier 88 Investment Partners reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Pier 88 Investment Partners sold 1,840 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $161K.
Pier 88 Investment Partners first reported a position in BioMarin Pharmaceuticals in Q1 2023 and held it in 5 quarters.
Pier 88 Investment Partners's BioMarin Pharmaceuticals position peaked at $387K in Q3 2023.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Pier 88 Investment Partners's 13F filing for Q2 2024, filed 6 Aug 2024.